Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels
Open Access
- 6 January 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 54 (4) , 353-360
Abstract
We monitored trough voriconazole serum concentrations from 107 patients (n = 258 samples) at 6 hospitals in Madrid. Most of the patients were male (67%) and had the following underlying conditions: hematological cancer (42%), solid organ transplantation (15%), chronic obstructive pulmonary disease (14%), human immunodeficiency virus infection (8.4%), solid cancer (5.6%), and other (29%). The indication for voriconazole administration was aspergillosis treatment (74.6%) and prophylaxis (14%). The main reasons for voriconazole trough drug monitoring were initiation of treatment/prophylaxis (33%), patient monitoring (47%), and suspected toxicity (3.5%). Levels (μg/ml) were subtherapeutic (5.5; 10.5%). The samples percentage with on-target levels was significantly lower for the first sample than for subsequent samples (62.6% vs. 77.5%). “Subsequent samples,” “admission in nonpediatric wards,” “voriconazole used for treatment of invasive aspergillosis,” and “use of proton pump inhibitors” were predictors of voriconazole therapeutic levels (≥1 μg/ml).Keywords
This publication has 16 references indexed in Scilit:
- Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospitalEnfermedades Infecciosas y Microbiología Clínica, 2015
- Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical MycologyJournal of Antimicrobial Chemotherapy, 2013
- Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological MalignanciesAntimicrobial Agents and Chemotherapy, 2013
- Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus InfectionsAntimicrobial Agents and Chemotherapy, 2012
- Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patientsJournal of Antimicrobial Chemotherapy, 2012
- The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled TrialClinical Infectious Diseases, 2012
- Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experienceMycoses, 2012
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety OutcomesClinical Infectious Diseases, 2008
- Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipientsCancer, 2007
- Effect of omeprazole on the steady‐state pharmacokinetics of voriconazoleBritish Journal of Clinical Pharmacology, 2003